Abingdon Health PLC Update on AffiDX(R) SARS-CoV-2 antigen LFT (8874X)
10 January 2022 - 6:05PM
UK Regulatory
TIDMABDX
RNS Number : 8874X
Abingdon Health PLC
10 January 2022
Abingdon Health plc
("Abingdon" or "the Company")
Update on AffiDX(R) SARS-CoV-2 antigen lateral flow test
Technical transfer completed mid-December as planned
Sales of AffiDX(R) paused by Avacta following Omicron
sensitivity analysis
York, U.K. 10 January 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, provides the following update on Avacta
Group plc's ("Avacta") AffiDX(R) SARS-CoV-2 antigen lateral flow
test:
Completion of Technical Transfer
Abingdon confirms that it completed the technical transfer of
the AffiDX(R) SARS-CoV-2 antigen lateral flow test assay product as
planned. Technical transfer is the process of taking a developed
product and optimising all processes and elements for mass
manufacture. The final technical transfer batches were shipped to
Avacta in mid-December 2021 with the products adhering to defined
specifications and passing all quality control procedures.
Sensitivity of AffiDX(R) SARS-CoV-2 antigen lateral flow
test
Abingdon also notes the announcement from Avacta this morning in
relation to their AffiDX(R) SARS-CoV-2 antigen lateral flow test,
which highlights that the sensitivity of the test is reduced at
lower viral loads when identifying the Omicron variant, compared to
the test's sensitivity with previous variants. The Company
understands this is a characteristic reported for other lateral
flow tests already on the market.
The Company notes that Avacta's Affimer(R) reagent in the
AffiDX(R) test detects the Omicron variant with the same
sensitivity as the Delta variant, and that it is the performance of
the antibody, which pairs with the Affimer(R) in the test, that has
been affected by the additional Omicron mutations. The Company also
notes that Avacta has independently taken the decision to pause
sales of the AffiDX(R) antigen test whilst it replaces the antibody
in the product to ensure that its performance with the Omicron
variant matches the high performance with previous mutations.
Abingdon scientists will work with Avacta to accelerate the
process of replacing the antibody in the current assay format, and
complete the process of technology transfer with this new
specification.
COVID-19 Antigen Testing Products
The Company has two projects in COVID-19 antigen testing. These
two projects involve the scale-up and technical transfer to
manufacture for the AffiDX(R) SARS-CoV-2 antigen lateral flow test
and for the Vatic KnowNow(TM) rapid antigen test developed by Vatic
Health Limited which uses a saliva sample. The process of technical
transfer for the Vatic KnowNow(TM) rapid antigen test remains on
track with completion anticipated during calendar Q1 2022.
According to Vatic the KnowNow test mimics the means through which
the virus interacts with the surface of a human cell in order to
detect it. As a result, they expect that it will continue to
identify the SARS-CoV-2 virus even in the face of further potential
mutations in the future.
Abingdon also has a pipeline of other non-COVID-19 contract
service opportunities that it will seek to bring through technical
transfer and into manufacture in due course.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Christopher Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Marriage 082
Alice Woodings Mob: +44 (0)7407 804 654
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via the Regulatory Information Service, this inside information is
now considered to be in the public domain.
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEADFNEEDAEAA
(END) Dow Jones Newswires
January 10, 2022 02:05 ET (07:05 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024